Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults &#8805;50â¯years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].

Maréchal, Céline; Lal, Himal; Poder, Airi; Ferguson, Murdo; Enweonye, Igwebuike; Heineman, Thomas C; Hervé, Caroline; Rheault, Paul; Talli, Jaak; Wauters, Dominique; Oostvogels, Lidia

Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50â¯years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286].

Maréchal, Céline; Lal, Himal; Poder, Airi; Ferguson, Murdo; Enweonye, Igwebuike; Heineman, Thomas C; Hervé, Caroline; Rheault, Paul; Talli, Jaak; Wauters, Dominique; Oostvogels, Lidia.

Afiliação

Maréchal C; Business and Decision Life Sciences for GSK, Wavre, Belgium. Electronic address: celine.x.marechal@gsk.com.
Lal H; GSK, King of Prussia, PA, USA.
Poder A; Clinical Research Center, Tartu, Estonia.
Ferguson M; Colchester Research Group, Truro, Nova Scotia, Canada.
Enweonye I; GSK, Amsterdam, the Netherlands.
Heineman TC; GSK, King of Prussia, PA, USA.
Hervé C; GSK, Wavre, Belgium.
Rheault P; Medicor Research Inc., Sudbury, Ontario, Canada.
Talli J; Innomedica Medical Center, Tallinn, Estonia.
Wauters D; GSK, Wavre, Belgium.
Oostvogels L; GSK, Wavre, Belgium.

Vaccine ; 37(9): 1252-1253, 2019 Feb 21.

Article em En | MEDLINE | ID: mdl-30711316

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2019 Tipo de documento: Article